Michael Joffre

I'll research this attorney before writing the summary.

Let me dig into the tracked cases and any notable outcomes.

Let me verify his role in the tracked cases and other notable matters.

Michael E. Joffre, Ph.D. — Sterne, Kessler, Goldstein & Fox (Director; Co-Chair, Appellate Practice)

Focus areas. Joffre's practice is patent and IP litigation with a substantial appellate component. Firm and ranking-guide profiles describe him handling microprocessor, telecommunications/network, computer software, mechanical-device and consumer-product matters, as well as pharmaceutical cases arising under the Hatch-Waxman/ANDA framework (IP Stars; Sterne Kessler; IAM Patent 1000, which lists him in its D.C. litigation band). He appears across district courts (Delaware, Texas, California, Wisconsin, New Jersey), the ITC, the PTAB, the Federal Circuit, and — per his firm bios — the Supreme Court at both certiorari and merits stages. The tracked case list's only identified subject matter is a pharmaceutical ANDA dispute, consistent with his generics-side experience rather than Wi-Fi/standards work.

Side of the "v." The tracked data show 0 plaintiff-side and 2 defendant-side appearances, and that defense orientation matches his documented background: Law360's 2017 report on his move to Sterne Kessler described him as having developed ANDA expertise acting for generic pharmaceutical companies, and his current firm bio still frames his pharma work as counseling generics. That said, the practice is not strictly one-way — Sterne Kessler press materials identify him as part of the team representing patent owner/plaintiff RoboticVISIONTech in its Delaware suits against ABB (settled March 2025) and in defending RVT's patent in IPR2023-01426; and at Kellogg Huber he represented Limelight Networks, the accused infringer, in the Supreme Court divided-infringement case (source for the Limelight representation is a secondary report quoting a Law360-style counsel list, so treat that detail as lower-confidence).

Firm context. Joffre has been a Director at Sterne Kessler since January 2017, where he co-chairs the Appellate Practice Group and sits in the Trial & Appellate Practice Group. Before that he was at the litigation boutique Kellogg, Huber, Hansen, Todd, Evans & Figel, from which he and J.C. Rozendaal moved to Sterne Kessler together. He is not an in-house attorney.

Notable tracked matters and outcomes. Veloxis Pharmaceuticals, Inc. v. Sun Pharmaceutical Industries Ltd. (D. Del. 1:24-cv-00726), an ANDA/§ 271(e)(2) case over tacrolimus (Envarsus XR) patents, is listed in the tracked data with Joffre on the defendant side as of counsel; the docket shows the case terminated by stipulated dismissal and consent judgment in April 2026. Note a verification gap: public docket summaries I reviewed list other firms (Richards Layton; Kratz & Barry) as Sun's trial counsel and do not show Joffre appearing at the district court level, so his involvement may have been appellate, consultative, or later-stage. The second tracked entry is an untitled defendant-side matter in which he is listed as Director.

PTAB/IPR. He is active in post-grant work and in appeals from it: he has argued before the PTAB, and the RVT matter included a successful opposition to institution of ABB's IPR petition. He also edits/contributes to Sterne Kessler's annual Federal Circuit Appeals from the PTAB and ITC year-in-review (including its data-and-trends work on AIA PTAB appeals), and has authored commentary on Federal Circuit decisions such as In re Cellect.

Bar and education. District of Columbia and Massachusetts (admitted 2005); also reported as admitted before the Supreme Court, the First and Federal Circuits, D.D.C., and D. Mass. J.D., Harvard Law School (2004); Ph.D. in astrophysics, University of Chicago; B.S., MIT. He clerked for Judge William C. Bryson on the Federal Circuit, 2004–2005.